Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Ernst A Lien"'
Autor:
Tomm Bernklev, Jan Terje Kvaløy, Timothy L Lash, Gunnar Mellgren, Thomas Helland, Bjornar Gilje, Turid Aas, Einar Gudlaugsson, Emiel A M Janssen, Kirsten Lode, Birgitta Haga Gripsrud, Jørn Vegard Sagen, Håvard Søiland, Finn Magnus Eliassen, Magnus Hagland, Oddmund Nordgård, Siri Lunde, Tone Hoel Lende, Kjersti Tjensvoll, Kristin Jonsdottir, Kari Britt Hagen, Ragna Lind, Anette Heie, Marie Austdal, Nina Gran Egeland, Linn Skartveit, Ann Cathrine Kroksveen, Satu Oltedal, Ernst A Lien, Linda Sleire
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Breast cancer is still the most common malignancy among women worldwide. The Prospective Breast Cancer Biobank (PBCB) collects blood and urine from patients with breast cancer every 6 or 12 months for 11 years from 2011 to 2030 at two un
Externí odkaz:
https://doaj.org/article/aa5275a655f8481d8710bf87d934c304
Autor:
Thomas Helland, Jennifer Gjerde, Simon Dankel, Ingvild S Fenne, Linn Skartveit, Andreas Drangevåg, Olivera Bozickovic, Marianne Hauglid Flågeng, Håvard Søiland, Gunnar Mellgren, Ernst A Lien
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122339 (2015)
INTRODUCTION:Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-dem
Externí odkaz:
https://doaj.org/article/fb52e9f7d3184425ae1d8a60233d04aa
Autor:
Monika H E Christensen, Ellen M Apalset, Yngve Nordbø, Jan Erik Varhaug, Gunnar Mellgren, Ernst A Lien
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56019 (2013)
OBJECTIVE: Parathyroid hormone (PTH) and vitamin D are the most important hormones regulating calcium metabolism. In primary hyperparathyroidism (PHPT) excessive amounts of PTH are produced. Bone turnover is enhanced, leading to reduced bone mineral
Externí odkaz:
https://doaj.org/article/36f00105e76a4d1c80e735762dec4dc2
Autor:
Monika H E Christensen, Simon N Dankel, Yngve Nordbø, Jan Erik Varhaug, Bjørg Almås, Ernst A Lien, Gunnar Mellgren
Publikováno v:
PLoS ONE, Vol 6, Iss 6, p e20481 (2011)
BACKGROUND: Primary hyperparathyroidism (PHPT) is characterised by increased production of parathyroid hormone (PTH) resulting in elevated serum calcium levels. The influence on bone metabolism with altered bone resorption is the most studied clinica
Externí odkaz:
https://doaj.org/article/f5b554069225447c95d9669a1a9cb040
Autor:
Fedro Alessandro Peccatori, Giovanni Codacci-Pisanelli, Gunnar Mellgren, Barbara Buonomo, Eleonora Baldassarre, Ernst Asbjorn Lien, Ersilia Bifulco, Steinar Hustad, Emil Zachariassen, Harriet Johansson, Thomas Helland
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
BackgroundBreast cancer represents the most frequent neoplasm diagnosed in women of childbearing age. When the tumour is oestrogen receptor-positive, tamoxifen is among the recommended endocrine treatments. Lactating women are advised not to breastfe
Externí odkaz:
https://doaj.org/article/aae6a0e449574be98002ee46cea83f7f
Autor:
Thomas Helland, Nina Henne, Ersilia Bifulco, Bjørn Naume, Elin Borgen, Vessela N. Kristensen, Jan T. Kvaløy, Timothy L. Lash, Grethe I. G. Alnæs, Ron H. van Schaik, Emiel A. M. Janssen, Steinar Hustad, Ernst A. Lien, Gunnar Mellgren, Håvard Søiland
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of
Externí odkaz:
https://doaj.org/article/d87f43f94ed34b168499025417929529
Autor:
Ernst A. Lien, Kari Britt Hagen, Gunnar Mellgren, Martha Eimstad Haugstøyl, Jennifer Gjerde, Siri Lunde, Birgitta Haga Gripsrud, Ersilia Bifulco, Kirsten Lode, Turid Aas, Håvard Søiland, Emiel A. M. Janssen, Tone Hoel Lende, Ragna Lind, Janne Jonassen, Kristin Jonsdottir, Steinar Hustad, Jan Terje Kvaløy, Thomas Helland
Publikováno v:
Breast Cancer Research and Treatment. 177:185-195
Tamoxifen is an important targeted endocrine therapy in breast cancer. However, side effects and early discontinuation of tamoxifen remains a barrier for obtaining the improved outcome benefits of long-term tamoxifen treatment. Biomarkers predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32c0ce2a7c9afd875791d064fda56fe0
https://doi.org/10.1007/s10549-019-05294-w
https://doi.org/10.1007/s10549-019-05294-w
Autor:
Håvard Søiland, Emiel A M Janssen, Thomas Helland, Finn Magnus Eliassen, Magnus Hagland, Oddmund Nordgård, Siri Lunde, Tone Hoel Lende, Jørn Vegard Sagen, Kjersti Tjensvoll, Bjørnar Gilje, Kristin Jonsdottir, Einar Gudlaugsson, Kirsten Lode, Kari Britt Hagen, Birgitta Haga Gripsrud, Ragna Lind, Anette Heie, Turid Aas, Marie Austdal, Nina Gran Egeland, Tomm Bernklev, Timothy L Lash, Linn Skartveit, Ann Cathrine Kroksveen, Satu Oltedal, Jan Terje Kvaløy, Ernst A Lien, Linda Sleire, Gunnar Mellgren
Publikováno v:
BMJ Open. 12:e054404
IntroductionBreast cancer is still the most common malignancy among women worldwide. The Prospective Breast Cancer Biobank (PBCB) collects blood and urine from patients with breast cancer every 6 or 12 months for 11 years from 2011 to 2030 at two uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b8d1fa6d51af819429ad47425e3c98
https://doi.org/10.1136/bmjopen-2021-054404
https://doi.org/10.1136/bmjopen-2021-054404
Autor:
Gunnar Mellgren, Harriet Johansson, Barbara Buonomo, Eleonora Baldassarre, Thomas Helland, Giovanni Codacci-Pisanelli, Steinar Hustad, Ernst A. Lien, Fedro A. Peccatori, Emil Zachariassen, Ersilia Bifulco
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
ESMO Open
ESMO Open
Background Breast cancer represents the most frequent neoplasm diagnosed in women of childbearing age. When the tumour is oestrogen receptor-positive, tamoxifen is among the recommended endocrine treatments. Lactating women are advised not to breastf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e51c15824bbde532996c5b37a9b9af0d
https://esmoopen.bmj.com/content/5/5/e000859.full
https://esmoopen.bmj.com/content/5/5/e000859.full
Autor:
Thomas, Helland, Kari Britt, Hagen, Martha Eimstad, Haugstøyl, Jan Terje, Kvaløy, Siri, Lunde, Kirsten, Lode, Ragna Anne, Lind, Birgitta Haga, Gripsrud, Kristin, Jonsdottir, Jennifer, Gjerde, Ersilia, Bifulco, Steinar, Hustad, Janne, Jonassen, Turid, Aas, Tone Hoel, Lende, Ernst Asbjørn, Lien, Emiel Adrianus Maria, Janssen, Håvard, Søiland, Gunnar, Mellgren
Publikováno v:
Breast cancer research and treatment. 177(1)
Tamoxifen is an important targeted endocrine therapy in breast cancer. However, side effects and early discontinuation of tamoxifen remains a barrier for obtaining the improved outcome benefits of long-term tamoxifen treatment. Biomarkers predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::586687122bcf75b7849e5af8507de05a
https://pubmed.ncbi.nlm.nih.gov/31144152
https://pubmed.ncbi.nlm.nih.gov/31144152